Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Japan Tobacco Pharma DELEGATE(S) Yuji Kando Shuichi Kotaka, Manager, Pharmaceutical Business Development 2-2-1, Toranomon, Minato-ku Tokyo 105-8422 Japan www.jt.com Incorporated: 1985 Employees: 7100 Ownership: Public Tokyo Stock Exchange: 2914 MISSION/BACKGROUND The Pharmaceutical Division of Japan Tobacco is a fully-integrated pharmaceutical entity dedicated to the discovery, development and marketing of novel human therapeutics. Our focus is on the identification of small molecule, orally available drugs to treat a variety of diseases, including: metabolic diseases (diabetes, obesity, dyslipidemia, osteoporosis, etc.); autoimmune/inflammatory diseases; and certain viral diseases (HIV infection and hepatitis C). Our sales franchises include products sold by our marketing subsidiary Torii Pharmaceutical for: renal diseases (hemodialysis patients) and urology; dermatology; infectious diseases (such as HIV); surgery and intensive care; and gastrointestinal diseases. JT seeks partnering opportunities to facilitate new drug discovery and development, such as products in early-stage development, new lead compounds, new drug targets, in vivo and in vitro assays, compound libraries, etc. JT also seeks products in late-stage development for Japanese market to be launched by Torii. TECHNOLOGY JT is highly oriented to R&D on its own, and has all the capabilities and technologies necessary for small moleule drug discovery and development. JT's preclinical R&D work is performed at its Central Pharmaceutical Research Institute, of which main facility is located near Osaka. Akros Pharma, which is a wholly-owned subsidiary of JT located in Princeton, New Jersey, conducts clinical development of JT compounds in the U.S. and Europe. Torii Pharmaceutical, one of the oldest pharmaceutical companies in Japan, is engaged in sales and marketing of products developed by JT inside the country as mentioned above. ALLIANCES JT has successfully established a number of strategic alliances, including product and technology licensing arrangements, research collaborations, funding and joint ventures with several pharmaceutical and biotech companies outside of Japan including: Gilead, Keryx, Roche, MedImmune, and GlaxoSmithKline. Company Profiles – 50